174 related articles for article (PubMed ID: 9476037)
1. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol.
Paar WD; Poche S; Gerloff J; Dengler HJ
Eur J Clin Pharmacol; 1997; 53(3-4):235-9. PubMed ID: 9476037
[TBL] [Abstract][Full Text] [Related]
2. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
4. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
[TBL] [Abstract][Full Text] [Related]
5. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood.
Levo A; Koski A; Ojanperä I; Vuori E; Sajantila A
Forensic Sci Int; 2003 Jul; 135(1):9-15. PubMed ID: 12893130
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
8. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
9. Modelling the pharmacokinetics of tramadol: on the difference between CYP2D6 extensive and poor metabolizers.
Di Patti F; Fanelli D; Pedersen RS; Giuliani C; Torricelli F
J Theor Biol; 2008 Oct; 254(3):568-74. PubMed ID: 18640130
[TBL] [Abstract][Full Text] [Related]
10. The hypoalgesic effect of tramadol in relation to CYP2D6.
Poulsen L; Arendt-Nielsen L; Brøsen K; Sindrup SH
Clin Pharmacol Ther; 1996 Dec; 60(6):636-44. PubMed ID: 8988065
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
12. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6.
Enggaard TP; Poulsen L; Arendt-Nielsen L; Brøsen K; Ossig J; Sindrup SH
Anesth Analg; 2006 Jan; 102(1):146-50. PubMed ID: 16368820
[TBL] [Abstract][Full Text] [Related]
13. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants.
Allegaert K; van Schaik RH; Vermeersch S; Verbesselt R; Cossey V; Vanhole C; van Fessem M; de Hoon J; van den Anker JN
Pediatr Res; 2008 Jun; 63(6):674-9. PubMed ID: 18317231
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
15. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.
Vevelstad M; Pettersen S; Tallaksen C; Brørs O
Eur J Clin Pharmacol; 2009 Aug; 65(8):795-801. PubMed ID: 19308365
[TBL] [Abstract][Full Text] [Related]
16. Miotic action of tramadol is determined by CYP2D6 genotype.
Slanar O; Nobilis M; Kvetina J; Mikoviny R; Zima T; Idle JR; Perlík F
Physiol Res; 2007; 56(1):129-136. PubMed ID: 16497087
[TBL] [Abstract][Full Text] [Related]
17. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
18. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
Srinivas NR
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
[TBL] [Abstract][Full Text] [Related]
19. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.
Tzvetkov MV; Saadatmand AR; Lötsch J; Tegeder I; Stingl JC; Brockmöller J
Clin Pharmacol Ther; 2011 Jul; 90(1):143-50. PubMed ID: 21562485
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
